Expert Insights and Best Practices in the Diagnosis of Unresectable Early-Stage NSCLC

Video content above is prompted by the following:

Diagnostic Workup for Unresectable Stage III NSCLC

Importance of Proper Staging

Accurate staging for NSCLC is critical as it:

• Determines treatment approach and prognosis
• Identifies appropriate candidates for curative-intent treatment
• Prevents futile surgery in patients with mediastinal involvement
• Guides selection of multimodality therapy options

Initial Evaluation

• Thorough History and Physical Examination
  • Assess performance status (ECOG/KPS)
  • Evaluate comorbidities affecting treatment tolerance
  • Document smoking history and occupational exposures
• Laboratory Studies
  • Complete blood count
  • Comprehensive metabolic panel
  • Pulmonary function tests (especially if considering surgery or radiation)

Imaging Studies

• Chest CT with Contrast
  • High-resolution imaging of primary tumor and mediastinum
  • Assessment of T stage and nodal involvement
• PET-CT Scan
  • Standard for detecting distant metastases
  • Improved sensitivity for identifying involved lymph nodes
  • Essential for identifying occult metastatic disease
  • Should cover from base of skull to mid thighs
• Brain MRI With Contrast
  • Mandatory for all patients with stage III disease
  • Up to 20% of NSCLC patients have brain metastases at diagnosis

Tissue Diagnosis and Molecular Assessment

• Core Needle Biopsy/Bronchoscopy
  • Obtain adequate tissue for histologic confirmation
  • Essential for molecular and immunohistochemical analysis
• Molecular Testing (required for all nonsquamous NSCLC)
  • EGFR, ALK, ROS1, BRAF mutations
  • NTRK gene fusions
  • Consider broader next-generation sequencing panel
• PD-L1 Testing
  • Mandatory for all NSCLC patients
  • Guides immunotherapy decisions

Mediastinal Staging

• Invasive Mediastinal Staging (critical for stage III disease)
  • Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
  • Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA)
  • Mediastinoscopy when EBUS/EUS is negative, but suspicion remains high
• Indications for Invasive Mediastinal Assessment
  • Clinical N1-3 disease
  • Central tumors
  • Tumors >3 cm (especially adenocarcinoma)
  • PET-positive mediastinal nodes

Additional Considerations

• Multidisciplinary Tumor Board Review
  • Essential for optimal treatment planning
  • Should include thoracic surgery, radiation oncology, medical oncology, pathology, and radiology
• Cardiopulmonary Assessment
  • Comprehensive evaluation for patients being considered for multimodality treatment
  • Assessment of radiation field overlap with critical cardiac structures
• Nutritional Evaluation
  • Essential for patients likely to receive concurrent chemoradiation

Unresectable Stage III Determination Criteria

Stage III NSCLC is typically considered unresectable with:

• T4 lesions with involvement of heart, great vessels, trachea, carina, esophagus, vertebral body
• Extensive mediastinal involvement (N2/N3)
• Contralateral hilar or supraclavicular nodal involvement
• Malignant pleural/pericardial effusion
• Poor performance status or medical inoperability